Back to News
Market Impact: 0.1
Nexentis: MitoCareX Completes Initial AI-Powered Computational Screening Milestone with Boltz
Source: globenewswire.com
Healthcare & BiotechTechnology & Innovation
MitoCareX described preliminary computational findings as encouraging for further computational analysis and experimental investigation, while noting they have not yet been experimentally validated.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.10
More News
- Stocks slump, bonds leap as AI giants’ spending spooks investors
- PC chip plunge wipes out a quarter of Intel’s value
- Daiichi Sankyo’s first-half profit rises on cancer drug growth; shares up
- Intel plunges on a major guidance miss. What went wrong — and how to proceed
- Japan’s Nikkei slumps 3% as tech stocks tumble on AI worries
- Starbucks serves up a solid quarter and full-year outlook. Why we're staying invested